Compare EFSC & SLNO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | EFSC | SLNO |
|---|---|---|
| Founded | 1988 | 1999 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.1B | 2.3B |
| IPO Year | 1999 | 2014 |
| Metric | EFSC | SLNO |
|---|---|---|
| Price | $57.75 | $43.14 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 10 |
| Target Price | $65.67 | ★ $112.70 |
| AVG Volume (30 Days) | 146.9K | ★ 1.5M |
| Earning Date | 01-26-2026 | 02-26-2026 |
| Dividend Yield | ★ 2.21% | N/A |
| EPS Growth | ★ 8.68 | N/A |
| EPS | ★ 5.13 | N/A |
| Revenue | ★ $646,694,000.00 | $98,675,000.00 |
| Revenue This Year | $20.14 | N/A |
| Revenue Next Year | $5.15 | $156.76 |
| P/E Ratio | $11.29 | ★ N/A |
| Revenue Growth | ★ 9.31 | N/A |
| 52 Week Low | $45.22 | $39.43 |
| 52 Week High | $62.60 | $90.32 |
| Indicator | EFSC | SLNO |
|---|---|---|
| Relative Strength Index (RSI) | 62.70 | 40.70 |
| Support Level | $54.74 | $41.34 |
| Resistance Level | $56.49 | $44.16 |
| Average True Range (ATR) | 1.38 | 2.73 |
| MACD | 0.29 | 0.12 |
| Stochastic Oscillator | 93.15 | 33.67 |
Enterprise Financial Services Corporation is a financial holding company. It offers banking and wealth management services to individuals and business customers located in Arizona, California, Florida, Kansas, Missouri, Nevada, and New Mexico, in addition to loan and deposit production offices throughout the United States. The company offers a broad range of business and personal banking services including wealth management services. Lending services include commercial and industrial, commercial real estate, real estate construction and development, residential real estate and consumer loans.
Soleno Therapeutics Inc is a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases. Its product candidate DCCR (Diazoxide Choline) Extended-Release tablets, is a proprietary extended-release formulation of a crystalline salt of diazoxide. DCCR has demonstrated the ability to activate the KATP channel in the brain, pancreas, and fat tissue.